Hereditary Paraganglioma and Pheochromocytoma Panel
Use
The Hereditary Paraganglioma and Pheochromocytoma Panel is designed for individuals with clinical or suspected diagnoses of hereditary paraganglioma or pheochromocytoma. This includes individuals with multiple, multifocal, bilateral, early-onset (<45 years) or familial paragangliomas/pheochromocytomas, as well as those with extra-adrenal or metastatic paragangliomas/pheochromocytomas. It also targets individuals with SDHB-deficient paragangliomas/pheochromocytomas by immunohistochemistry and those with personal or family histories consistent with syndromic presentations (e.g., MEN1, MEN2, NF1, VHL, HLRCC).
Special Instructions
STAT testing option is available, which adds a surcharge but is not applied if the report is delivered after 16 days with a blood sample submitted. The PGselect Platform is used for the NGS with CNV method.
Limitations
The performance characteristics of this test have been validated under the accreditation of CAP and CLIA regulations. However, it has not been cleared or approved by the FDA, potentially limiting its application to NY state if approval is not secured.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided